Avenue Therapeutics Future Growth

Future criteria checks 0/6

Avenue Therapeutics is forecast to grow earnings and revenue by 7.9% and 85.7% per annum respectively while EPS is expected to grow by 31.3% per annum.

Key information

7.9%

Earnings growth rate

31.3%

EPS growth rate

Pharmaceuticals earnings growth	17.9%
Revenue growth rate	85.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:49Y0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-20	-20	N/A	1
12/31/2025	N/A	-16	-16	N/A	1
12/31/2024	N/A	-13	-13	N/A	1
12/31/2023	N/A	-10	-12	-9	N/A
9/30/2023	N/A	-10	-14	-11	N/A
6/30/2023	N/A	-12	-13	-11	N/A
3/31/2023	N/A	-8	-7	-7	N/A
12/31/2022	N/A	-4	-8	-8	N/A
9/30/2022	N/A	-5	-5	-5	N/A
6/30/2022	N/A	-5	-5	-5	N/A
3/31/2022	N/A	-6	-4	-4	N/A
12/31/2021	N/A	-4	-4	-4	N/A
9/30/2021	N/A	-4	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-5	-5	N/A
9/30/2020	N/A	-10	-8	-8	N/A
6/30/2020	N/A	-11	-9	-9	N/A
3/31/2020	N/A	-16	-22	-22	N/A
12/31/2019	N/A	-26	-26	-26	N/A
9/30/2019	N/A	-24	-23	-23	N/A
6/30/2019	N/A	-25	-25	-25	N/A
3/31/2019	N/A	-22	-17	-17	N/A
12/31/2018	N/A	-22	-18	-18	N/A
9/30/2018	N/A	-24	-21	-21	N/A
6/30/2018	N/A	-24	-19	-19	N/A
3/31/2018	N/A	-22	-14	-14	N/A
12/31/2017	N/A	-12	-7	-7	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-1	N/A
3/31/2017	N/A	-3	N/A	-1	N/A
12/31/2016	N/A	-3	N/A	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 49Y0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 49Y0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 49Y0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 49Y0 is forecast to have no revenue next year.

High Growth Revenue: 49Y0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 49Y0's Return on Equity is forecast to be high in 3 years time

Avenue Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Less than half of directors are independent

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies